A revised natural history model for primary sclerosing cholangitis

Mayo Clinic Proceedings

Volumn 75, Issue 7, 2000, Pages 688-694

  Kim, W Ray ^a   Therneau, Terry M ^a   Wiesner, Russell H ^a   Poterucha, John J ^a   Benson, Joanne T ^a   Malinchoc, Michael ^a   Larusso, Nicholas F ^a   Lindor, Keith D ^a   Dickson, E Rolland ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ACCURACY; ARTICLE; FOLLOW UP; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REPRODUCIBILITY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; VARICOSIS;

EID: 0033923645     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)64614-4     Document Type: Article

References (29)

1. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989; 10:430-436.
2. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710-1717.
3. Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology. 1992;103:1893-1901.
4. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610-615.
5. Lindor KD, Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Urosodiol for primary sclerosing cholangitis. N EnglJ Med. 1997;336:691-695.
6. Schluchter MD. Methods for the analysis of infomatively censored longitudinal data. Stat Med. 1992;! 1:1861-1870.
7. Robins JM. An analytic method for randomized trials with informative censoring: part 1. Lifetime Data Anal. 1995; 1:241-254.
8. Slud EV, Rubinstein LV. Dependent competing risks and summary survival curves. Biometrika. 1983;70:643-649.
9. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:l-7.
10. Markus BH, Dickson ER, Grambsch PM, et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med. 1989;320:1709-1713.
11. Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology. 1998;28: 33-38.
12. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994; 106:1284-1290.
13. Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997;3:628-637.
14. Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology. 1989; 10:846-850.
15. Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924-933.
16. Ludwig J, MacCarty RL, LaRusso NF, Krom RA, Wiesner RH. Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis. Hepatology. 1986;6:560-568.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Er JSurg. 1973;60:646-649.
18. Clermont RJ, Chalmers TC. The transaminase tests in liver disease. Medicine (Baltimore). 1967;46:197-207.
19. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G, Italian PSC Study Group. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. Eur J Gastroenterol Hepatol. 1996;8:685-691.
20. Poupon RE, Bonnand A-M, Heathcote EJ, Lindor KD, Poupon R. Prognostic factors in ursodeoxycholic acid treated patients with primary biliary cirrhosis [abstract]. Hepatology. 1997;26(program issue):400A. Abstract 1086.
21. Kim WR, Jorgensen RA, Malinchoc M, Benson JT, Dickson ER, Lindor KD. Are there patients with primary sclerosing cholangitis in whom ursodeoxycholic acid may be beneficial? [abstract]. Gastroenterology. 1997; 112(suppl):Al 301.
22. Chalasani N, Clark WS, Martin LG, et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology. 2000; 118:138144.
23. Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology. 1982;82:968-973.
24. Grace ND, American College of Gastroenterology Practice Parameters Committee. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol. 1997;92: 1081-1091.
25. Boyer TD. Natural history of portal hypertension. Clin Liver Dis. 1997; 1:31-44.
26. Sauer P, Theilmann L, Stremmel W, Benz C, Richter GM, Stiehl A. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology. 1997;! 13:1623-1631.
27. Abu-Elmagd KM, Malinchoc M, Dickson ER, et al. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet. 1993; 177:335-344.
28. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213:21-25.
29. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: a population-based study. Scand J Gastroenterol. 1997;32:1042-1045.